H.C. Wainwright analyst Edward White maintained a Buy rating on Mersana Therapeutics (NASDAQ:MRSN) Inc on Friday, setting a price target of $28, which is approximately 99.15% above the present share price of $14.06.
White expects Mersana Therapeutics Inc to post earnings per share (EPS) of -$0.59 for the third quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Mersana Therapeutics, with an average price target of $29.25.
The analysts price targets range from a high of $32 to a low of $27.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $11 thousand and a net profit of -$40.83 million. The company's market cap is $1.01 billion.
According to TipRanks.com, H.C. Wainwright analyst Edward White is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.3% and a 44.51% success rate.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.